UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

 

 

Agios Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, $0.001 par value

(Title of Class of Securities)

00847X104

(CUSIP Number)

Robert J. Hugin

Chairman of the Board,

President and Chief Executive Officer

Celgene Corporation

86 Morris Avenue

Summit, New Jersey 07901

(908) 673-9000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

December 16, 2014

(Date of Event Which Requires Filing of This Statement)

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g) check the following box:  ¨

 

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

 

 

 

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

---

SCHEDULE 13D

 

CUSIP No. 00847X104

 

1		Name of reporting person:   I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) CELGENE EUROPEAN INVESTMENT COMPANY LLC 90-0587060
2		Check the appropriate box if a member of a group*   (a)  ¨        (b)  x
3		SEC use only
4		Source of funds*   WC
5		Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)   ¨
6		Citizenship or place of organization   Delaware, U.S.A.
Number of shares beneficially owned by each reporting person with				7		Sole voting power   -0-
				8		Shared voting power   4,010,926
				9		Sole dispositive power   -0-
				10		Shared dispositive power   4,010,926
11		Aggregate amount beneficially owned by each reporting person   4,010,926
12		Check box if the aggregate amount in Row (9) excludes certain shares*   ¨
13		Percent of class represented by amount in Row (9)   11.0% (1)
14		Type of reporting person*   OO (limited liability company)

 

(1)

The percentage ownership is based upon 36,628,994 shares of Common Stock outstanding as of December 16, 2014, which includes (a) 34,642,539 shares of Common Stock outstanding as of September 30, 2014, as reported by Agios on its prospectus filed with the Securities and Exchange Commission on December 11, 2014, and (b) 1,986,455 shares of Common Stock issued by Agios on December 16, 2014.

---

CUSIP No. 00847X104

 

1		Name of reporting person:   I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) CELGENE ALPINE INVESTMENT CO., LLC 45-4054818
2		Check the appropriate box if a member of a group*   (a)  ¨        (b)  x
3		SEC use only
4		Source of funds*   WC
5		Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)   ¨
6		Citizenship or place of organization   Delaware, U.S.A.
Number of shares beneficially owned by each reporting person with				7		Sole voting power   -0-
				8		Shared voting power   708,333
				9		Sole dispositive power   -0-
				10		Shared dispositive power   708,333
11		Aggregate amount beneficially owned by each reporting person   708,333
12		Check box if the aggregate amount in Row (9) excludes certain shares*   ¨
13		Percent of class represented by amount in Row (9)   1.9% (1)
14		Type of reporting person*   OO (limited liability company)

 

(1)

The percentage ownership is based upon 36,628,994 shares of Common Stock outstanding as of December 16, 2014, which includes (a) 34,642,539 shares of Common Stock outstanding as of September 30, 2014, as reported by Agios on its prospectus filed with the Securities and Exchange Commission on December 11, 2014, and (b) 1,986,455 shares of Common Stock issued by Agios on December 16, 2014.

---

CUSIP No. 00847X104

 

1		Name of reporting person:   I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) CELGENE CORPORATION 22-2711928
2		Check the appropriate box if a member of a group*   (a)  ¨        (b)  x
3		SEC use only
4		Source of funds*   WC
5		Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)   ¨
6		Citizenship or place of organization   Delaware, U.S.A.
Number of shares beneficially owned by each reporting person with				7		Sole voting power   -523,445-
				8		Shared voting power   4,719,259
				9		Sole dispositive power   -523,445-
				10		Shared dispositive power   4,719,259
11		Aggregate amount beneficially owned by each reporting person   5,242,704
12		Check box if the aggregate amount in Row (9) excludes certain shares*   ¨
13		Percent of class represented by amount in Row (9)   14.3% (1)
14		Type of reporting person*   CO

 

(1)

The percentage ownership is based upon 36,628,994 shares of Common Stock outstanding as of December 16, 2014, which includes (a) 34,642,539 shares of Common Stock outstanding as of September 30, 2014, as reported by Agios on its prospectus filed with the Securities and Exchange Commission on December 11, 2014, and (b) 1,986,455 shares of Common Stock issued by Agios on December 16, 2014.

---

This Amendment No. 2 amends the Schedule 13D (the “Schedule 13D”) filed with the Securities and Exchange Commission (the “Commission”) on August 6, 2013 by Celgene European Investment Company LLC, Celgene Alpine Investment Co., LLC (“Celgene Alpine”) and Celgene Corporation (“Celgene”), as amended by Amendment No. 1 thereto filed with the Commission on April 30, 2014, with respect to common stock, par value $0.001 per share (“Common Stock”), of Agios Pharmaceuticals, Inc., a Delaware corporation (“Agios”). Capitalized terms used, but not defined herein, have the meanings ascribed to them in the Schedule 13D.

Item 1. Security and Issuer.

No modification.

Item 2. Identity and Background.

No modification.

Item 3. Source and Amount of Funds or Other Consideration.

No modification.

Item 4. Purpose of Transaction.

Item 4 is hereby amended and supplemented by adding the following:

On December 16, 2014, Agios completed its underwritten public offering (the “Offering”) of 1,986,455 shares of Common Stock at a public offering price of $110.75 per share, and Celgene purchased (the “Purchase”) 228,645 shares of Common Stock at a purchase price of $110.75 per share in the Offering for investment purposes. Following the Offering and the Purchase, Celgene beneficially owns 523,445 shares of Common Stock and shares beneficial ownership of 4,719,259 shares of Common Stock, collectively representing approximately 14.3% of the shares of Common Stock outstanding as of December 16, 2014, which includes (a) 34,642,539 shares of Common Stock outstanding as of September 30, 2014, as reported by Agios on its prospectus filed with the Commission on December 11, 2014, and (b) 1,986,455 shares of Common Stock issued by Agios on December 16, 2014.

Item 5. Interest in Securities of the Issuer.

Item 5(a)-(c) is hereby amended and supplemented as follows:

On December 16, 2014, Agios completed the Offering and Celgene completed the Purchase. Following the Offering and the Purchase, Celgene beneficially owns 523,445 shares of Common Stock and shares beneficial ownership of 4,719,259 shares of Common Stock, collectively representing approximately 14.3% of the shares of Common Stock outstanding as of December 16, 2014, which includes (a) 34,642,539 shares of Common Stock outstanding as of September 30, 2014, as reported by Agios on its prospectus filed with the Commission on December 11, 2014, and (b) 1,986,455 shares of Common Stock issued by Agios on December 16, 2014.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

No modification.

Item 7. Material to Be Filed as Exhibits.

No modification.

---

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.